CRISPR Cas9-guided chromatin immunoprecipitation identifies miR483 as an epigenetic modulator of IGF2 imprinting in tumors

Oncotarget

Volumn 8, Issue 21, 2017, Pages 34177-34190

  Zhang, Yiqun ^a,b   Hu, Ji Fan ^a,b   Wang, Hong ^a,b   Cui, Jiuwei ^a   Gao, Sujun ^a   Hoffman, Andrew R ^b   Li, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allelic expression; Epigenetics; Histone K27 methylation; IGF2 imprinting; Tumor

Indexed keywords

CASPASE 9; CRISPR ASSOCIATED PROTEIN; MEMBRANE PROTEIN; MICRORNA; MICRORNA 483; PROTEIN SUZ12; TRANSCRIPTION FACTOR CTCF; UNCLASSIFIED DRUG; IGF2 PROTEIN, HUMAN; MIRN483 MICRORNA, HUMAN; SOMATOMEDIN B;

ANALYSIS OF VARIANCE; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DENSITOMETRY; DNA CLEAVAGE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENOME IMPRINTING; GENOTYPE; HUMAN; HUMAN CELL; IGF2 GENE; INTRON; MOLECULAR CLONING; ONCOGENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; CELL MOTION; CELL PROLIFERATION; CRISPR CAS SYSTEM; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HCT 116 CELL LINE; NEOPLASM; PROCEDURES;

CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CRISPR-CAS SYSTEMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HCT116 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MICRORNAS; NEOPLASMS; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 85019833205     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10918     Document Type: Article

References (68)

1. Feinberg AP. An epigenetic approach to cancer etiology. Cancer journal. 2007; 13:70-74
2. Bergman D, Halje M, Nordin M, Engstrom W. Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology. 2013; 59:240-249
3. Ribarska T, Bastian KM, Koch A, Schulz WA. Specific changes in the expression of imprinted genes in prostate cancer-implications for cancer progression and epigenetic regulation. Asian journal of andrology. 2012; 14:436-450
4. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 2010; 95:415-423
5. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005; 19:586-594
6. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102:972-980
7. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12:159-169
8. Pierre-Eugene C, Pagesy P, Nguyen TT, Neuille M, Tschank G, Tennagels N, Hampe C, Issad T. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One. 2012; 7:e41992
9. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res. 2010; 16:2999-3010
10. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica et biophysica acta. 2015; 1855:104-121
11. Rieder S, Michalski CW, Friess H, Kleeff J. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anti-cancer agents in medicinal chemistry. 2011; 11:427-433
12. Riccio A, Sparago A, Verde G, De Crescenzo A, Citro V, Cubellis MV, Ferrero GB, Silengo MC, Russo S, Larizza L, Cerrato F. Inherited and Sporadic Epimutations at the IGF2-H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumor. Endocrine development. 2009; 14:1-9
13. Hu JF, Vu TH, Hoffman AR. Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem. 1996; 271:18253-18262
14. Szabo PE, Tang SH, Silva FJ, Tsark WM, Mann JR. Role of CTCF binding sites in the Igf2/H19 imprinting control region. Mol Cell Biol. 2004; 24:4791-4800
15. Srivastava M, Hsieh S, Grinberg A, Williams-Simons L, Huang SP, Pfeifer K. H19 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19. Genes Dev. 2000; 14:1186-1195
16. Hofmann WK, Takeuchi S, Frantzen MA, Hoelzer D, Koeffler HP. Loss of genomic imprinting of insulinlike growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. Exp Hematol. 2002; 30:318-323
17. Chen HL, Li T, Qiu XW, Wu J, Ling JQ, Sun ZH, Wang W, Chen W, Hou A, Vu TH, Hoffman AR, Hu JF. Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J. 2006; 25:5329-5338
18. Cui H, Niemitz EL, Ravenel JD, Onyango P, Brandenburg SA, Lobanenkov VV, Feinberg AP. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site. Cancer Res. 2001; 61:4947-4950
19. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPRmediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013; 154:442-451
20. Graslund T, Li X, Magnenat L, Popkov M, Barbas CF, 3rd. Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. J Biol Chem. 2005; 280:3707-3714
21. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNAguided platform for sequence-specific control of gene expression. Cell. 2013; 152:1173-1183
22. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346:1258096
23. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157:1262-1278
24. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013; 10:957-963
25. Li T, Chen H, Li W, Cui J, Wang G, Hu X, Hoffman AR, Hu J. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet. 2014; 23:117-128
26. Vu TH, Hoffman AR. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature. 1994; 371:714-717
27. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012; 109:E2579-2586
28. Marraffini LA, Sontheimer EJ. CRISPR interference: RNAdirected adaptive immunity in bacteria and archaea. Nature reviews Genetics. 2010; 11:181-190
29. Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nature reviews Molecular cell biology. 2016; 17:5-15
30. Bono JM, Olesnicky EC, Matzkin LM. Connecting genotypes, phenotypes and fitness: harnessing the power of CRISPR/Cas9 genome editing. Molecular ecology. 2015; 24:3810-3822
31. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, Nagano T, Mancini-Dinardo D, Kanduri C. Kcnq1ot1 antisense noncoding RNA mediates lineagespecific transcriptional silencing through chromatin-level regulation. Molecular cell. 2008; 32:232-246
32. Moresi V, Marroncelli N, Coletti D, Adamo S. Regulation of skeletal muscle development and homeostasis by gene imprinting, histone acetylation and microRNA. Biochimica et biophysica acta. 2015; 1849:309-316
33. Ruhrmann S, Stridh P, Kular L, Jagodic M. Genomic imprinting: A missing piece of the Multiple Sclerosis puzzle? The international journal of biochemistry & cell biology. 2015; 67:49-57
34. Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, Maheswaran S, Diederichs S, Haber DA. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 2013; 27:2543-2548
35. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A. 2007; 104:3466-3471
36. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005; 307:1976-1978
37. Li T, Hu JF, Qiu X, Ling J, Chen H, Wang S, Hou A, Vu TH, Hoffman AR. CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol. 2008; 28:6473-6482
38. Zhang H, Niu B, Hu JF, Ge S, Wang H, Li T, Ling J, Steelman BN, Qian G, Hoffman AR. Interruption of intrachromosomal looping by CCCTC binding factor decoy proteins abrogates genomic imprinting of human insulinlike growth factor II. The Journal of cell biology. 2011; 193:475-487
39. Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang SD, Hu YZ, Zhou XX, Jia WH. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chinese journal of cancer. 2014; 33:330-338
40. Warnecke-Eberz U, Chon SH, Holscher AH, Drebber U, Bollschweiler E. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour Biol. 2015; 36:4643-4653
41. Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, Satoh K. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. International journal of oncology. 2015; 46:539-547
42. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2011; 117:1630-1639
43. Seitz H. Redefining microRNA targets. Current biology: CB. 2009; 19:870-873
44. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113:673-676
45. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell. 2009; 136:26-36
46. Carthew RW. Gene regulation by microRNAs. Current opinion in genetics & development. 2006; 16:203-208
47. Archanioti P, Gazouli M, Theodoropoulos G, Vaiopoulou A, Nikiteas N. Micro-RNAs as regulators and possible diagnostic bio-markers in inflammatory bowel disease. Journal of Crohn's & colitis. 2011; 5:520-524
48. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298:1039-1043
49. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell. 2002; 111:185-196
50. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004; 18:1592-1605
51. Zhang H, Niu B, Hu JF, Wang H, Ling J, Qian G, Ge S, Hoffman AR. Interruption of intrachromosomal looping by CTCF decoy proteins abrogates genomic imprinting of human insulin-like growth factor II. The Journal of cell biology. 2011; 193:475-487
52. Vu TH, Nguyen AH, Hoffman AR. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum Mol Genet. 2010; 19:901-919
53. Qiu X, Vu TH, Lu Q, Ling JQ, Li T, Hou A, Wang SK, Chen HL, Hu JF, Hoffman AR. A complex deoxyribonucleic Acid looping configuration associated with the silencing of the maternal igf2 allele. Mol Endocrinol. 2008; 22:1476-1488
54. Wang H, Ge S, Qian G, Li W, Cui J, Wang G, Hoffman AR, Hu JF. Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells. Exp Cell Res. 2015; 338:214-221
55. Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, Zhao Z, Lobanenkov V, Reik W, Ohlsson R. CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci U S A. 2006; 103:10684-10689
56. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, Cherry AM, Hoffman AR. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science. 2006; 312:269-272
57. Yoon YS, Jeong S, Rong Q, Park KY, Chung JH, Pfeifer K. Analysis of the H19ICR insulator. Mol Cell Biol. 2007; 27:3499-34510
58. Murrell A, Heeson S, Reik W. Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nat Genet. 2004; 36:889-893
59. Zhang H, Zeitz MJ, Wang H, Niu B, Ge S, Li W, Cui J, Wang G, Qian G, Higgins MJ, Fan X, Hoffman AR, Hu JF. Long noncoding RNA-mediated intrachromosomal interactions promote imprinting at the Kcnq1 locus. The Journal of cell biology. 2014; 204:61-75
60. Sun J, Li W, Sun Y, Yu D, Wen X, Wang H, Cui J, Wang G, Hoffman AR, Hu JF. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res. 2014; 42:9588-9601
61. Kang L, Sun J, Wen X, Cui J, Wang G, Hoffman AR, Hu JF, Li W. Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers. European journal of cancer. 2015; 51:260-270
62. Wang H, Li W, Guo R, Sun J, Cui J, Wang G, Hoffman AR, Hu JF. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies. Int J Cancer. 2014; 135:2783-2794
63. Zhang ZH, Niu B, Zeitz MJ, Ge S, Qian G, Higgins MJ, Hoffman AR, Hu JF. Long non-coding RNA Kcnq1ot1 regulates Kcnq1 imprinting by building a long-range intrachromosomal loop. The Journal of cell biology. 2014; 204:61-75
64. Zhang S, Zhong B, Chen M, Yang G, Li Y, Wang H, Wang G, Li W, Cui J, Hoffman AR, Hu J. Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer. 2014; 134:1583-1594
65. Zhang H, Jiao W, Sun L, Fan J, Chen M, Wang H, Xu X, Shen A, Li T, Niu B, Ge S, Li W, Cui J, Wang G, Sun J, Fan X, et al. Intrachromosomal Looping Is Required for Activation of Endogenous Pluripotency Genes during Reprogramming. Cell Stem Cell. 2013; 13:30-35
66. Yin H, Chen N, Guo R, Wang H, Li W, Wang G, Cui J, Jin H, Hu JF. Antitumor potential of a synthetic interferonalpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep. 2015; 5:16975
67. Zhai Y, Chen X, Yu D, Li T, Cui J, Wang G, Hu JF, Li W. Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress. Exp Cell Res. 2015; 337:61-67
68. Fujita T, Fujii H. Efficient isolation of specific genomic regions and identification of associated proteins by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Biochem Biophys Res Commun. 2013; 439:132-136